CN102133395B - Skeleton health-care product or medicinal composite and application thereof - Google Patents
Skeleton health-care product or medicinal composite and application thereof Download PDFInfo
- Publication number
- CN102133395B CN102133395B CN 201110066234 CN201110066234A CN102133395B CN 102133395 B CN102133395 B CN 102133395B CN 201110066234 CN201110066234 CN 201110066234 CN 201110066234 A CN201110066234 A CN 201110066234A CN 102133395 B CN102133395 B CN 102133395B
- Authority
- CN
- China
- Prior art keywords
- weight portions
- calcium
- weight
- bone
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a skeleton health-care product or a medicinal composite, which comprises the following raw materials in part by weight: 160,000 to 185,000 parts of calcium carbonate, 1 to 2 parts of vitamin D3, 11,000 to 13,000 parts of casein phosphoeptide, 30,000 to 50,000 parts of chondroitin sulfate, 80,000 to 100,000 parts of glucosamine hydrochloride, 50,000 to 70,000 parts of ossein and 1,150 to 1,500 parts of manganese chloride. The skeleton health-care product or the medicinal composite has a skillful and unique design, mutually-synergistic components and high bioavailability, can be used for increasing bone mineral density, relieving bone pain, restoring bone functions and improving immunity, treats the symptoms of osteoporosis, bone pain, loss of bone joint functions and the like, can be prepared into a compound preparation, does not have toxic or side effect, and is suitable for large-scale popularization and application.
Description
Technical field
The present invention relates to health-care product or pharmaceutical composition technical field, be particularly related to skeleton health-care product or pharmaceutical composition technical field, specifically refer to a kind of skeleton health-care product or pharmaceutical composition and application thereof, this skeleton health-care product or pharmaceutical composition can be used for increasing bone density and alleviate bone pain recovery bone function raising immunity.
Background technology
The osteoarthrosis such as osteoporosis have become one of most important public health problem of developed country, also are the more and more distinct issues that developing country need to face.American-European countries report, osteoporotic fracture can occur in 30% women and 12% man in life, the medical care expenses of spending at UK and USA up to 1,400,000,000 and 15,000,000,000 dollars.The hip fracture rate that recent Asia osteoporotic fracture Epidemiological study result shows Hong-Kong and Singapore is than having increased by 3 times the sixties in 20th century, and the change of the environmental factorss such as this mainly increases sharply with elderly population, life style is relevant.
Along with China's older population increases, the socioeconomic obvious change that develops rapidly with life style, change such as dietary structure, physical exertion minimizing etc., so that osteoporosis and serious consequence fracture thereof also become the more and more serious community health problem of China, therefore everybody should attract great attention, and prevents and treats early.
Therefore, need to provide a kind of skeleton health-care product or pharmaceutical composition, it can alleviate bone pain recovery bone function raising immunity for increasing bone density, thereby is that the guarantee human health is made certain contribution.
Summary of the invention
The objective of the invention is to have overcome above-mentioned shortcoming of the prior art, a kind of skeleton health-care product or pharmaceutical composition and application thereof are provided, this skeleton health-care product or pharmaceutical composition design ingenious uniqueness, mutually take between component together, bioavailability is high, can alleviate bone pain for increasing bone density and recover bone function raising immunity, obviously solve osteoporosis, bone pain, and the symptom such as osteoarthrosis afunction, and can be made into compound preparation, have no side effect, be suitable for large-scale promotion application.
To achieve these goals, in a first aspect of the present invention, provide a kind of skeleton health-care product or pharmaceutical composition, be characterized in, formed by the raw material of following portions by weight: the calcium carbonate of 160000～185000 weight portions, the vitamin D of 1～2 weight portion
3, the phosphopeptide caseinate of 11000～13000 weight portions, the chondroitin sulfate of 30000～50000 weight portions, the ossein of the glucosamine hydrochloride of 80000～100000 weight portions and 50000～70000 weight portions, the manganese chloride of 1150～1500 weight portions.
Preferably, described calcium carbonate is 168000～180000 weight portions, described vitamin D
3It is 1～2 weight portion, described phosphopeptide caseinate is 11500～12500 weight portions, described chondroitin sulfate is 40000～50000 weight portions, described glucosamine hydrochloride be 88000～95000 weight portions with described ossein be 55000～65000 weight portions, the manganese chloride of 1200～1450 weight portions.
Best, described calcium carbonate is 173333 weight portions, described vitamin D
3Be 1 weight portion, described phosphopeptide caseinate is 12000 weight portions, and described chondroitin sulfate is 46667 weight portions, described glucosamine hydrochloride be 93333 weight portions with described ossein be 60000 weight portions, described manganese chloride is 1333 weight portions.
Above-mentioned compound basis is as follows:
Modern medicine study proves that many factors can affect people's bone density: the living habit that (1) is bad: all can reduce bone density and then cause osteoporosis such as long-term excessive drinking and smoking.(2) trophic factor: the normal growth of osseous tissue and growth need an amount of calcium to take in, and only have the calcium of capacity to take the photograph the people in adolescence and just can reach best peak bone density.(3) exercise factor: motion is necessary to normal bone mineralising, and the positive outdoor exercise activity of adolescence is very definite on the impact of peak bone density.(4) endocrine hormone: androgen has been kept important regulating action to the growth of male's normal bone, metabolism, bone amount.This effect is by autoreceptor mediation, on the surface of the endotheliocyte of osteoblast, osteoclast, osteocyte, marrow stromal cell and blood vessel androgen receptor arranged all.Estrogen is to existing ER defective or synthetic estrogen.Parathyroid hormone can increase osteoblast number and activity, is converted into osteoblast by guiding bone lining cell *, and does not need to stimulate the propagation of precursor, can also stop osteoblast to be transferred and die, and plays an important role in the mineralising of regulating bone matrix.(5) oxidative stress more and more comes into one's own as an osteoporotic risk factor in recent years.There are some researches show that free radical too much during oxidative stress status can suppress osteoblastic differentiation in the bone marrow, stimulates simultaneously differentiation of osteoclast, makes Decrease of Bone Mineral Density, has promoted osteoporotic genesis.
A large amount of researchs prove that also many functional factors all have certain increase bone substance density improving function, but their mechanism is had nothing in common with each other: 1) calcium is the basic nutrition of maintaining bone density, also is an important dietary factors that affects bone density.When calcium absorption or calcium absorption deficiency, will bring out hyperparathyroidism, then cause mobilizing from the bone of skeleton, discharge more calcium to keep the calcium stable of serum.Therefore bone loss occurs.Therefore, the status of calcium in prevention and treatment osteoporosis is very important and irreplaceable; 2) body vitamin D
3Level and bone density, the strong density dependent of muscle, vitamin D
3Be the main adjusting factor of calcium absorption, can help absorption of human body calcium, effectively improve human bone mineral density and take in the peak value that calcium can be kept to the long duration bone density.Shortage or not enough human body also can cause the Secondary cases parathyroid function to increase to the incomplete absorption 10% of calcium, increase the bone conversion, promote bone loss, cause osteoporosis and fracture; 3) phosphopeptide caseinate promotes absorbing of the divalent minerals such as calcium; 4) chondroitin sulfate can promote in vivo osteoblastic propagation, promote osteoblastic mineralising, and chondroitin sulfate also has very strong antioxidant activity, and this all is conducive to the development of delaying osteoporosis and improves bone density; 5) glucosamine hydrochloride has very strong antioxidant activity, is conducive to the development of delaying osteoporosis, thereby relatively increases bone density; 6) bone collagen can make calcium effectively be deposited on the skeleton, improve the absorbance of calcium, the calcium that human body absorbs, the interconnect function by collagen protein is just effectively utilized by skeleton just, only have enough osseins of replenishing, the rational proportion of guarantee skeleton composition.7) manganese: be the composition that consists of the human body plurality of enzymes, the enzyme of especially synthetic cartilaginous tissue and the enzyme that promotes osteoblast activity, these two kinds of enzymes are good catalyst, can accelerate to promote the synthetic and bone calcium deposition of cartilage.Manganese can also promote the synthetic of superoxide dismutase, promotes albumen synthetic.
The compatibility relationship of skeleton health-care product of the present invention or pharmaceutical composition: formula components is from different perspectives, promotes the absorption of calcium and the deposition on skeleton by different mechanism, suppress dissolving and the loss of calcium, promote the formation of bone matrix, thereby bone density is increased, reduce bone pain, recover the bone function.Wherein, calcium carbonate is the calcium source that replenishes, directly for the low material base of bone density; Phosphopeptide caseinate and the absorption of vitamin D3 with different mechanism promotion calcium; Glucosamine hydrochloride and chondroitin sulfate mainly reduce the generation of Decrease of Bone Mineral Density with antioxidative mechanism; Ossein can make calcium effectively be deposited on the skeleton, the calcium that human body absorbs, and the interconnect function by collagen protein is just effectively utilized by skeleton just; Manganese can accelerate to promote the synthetic and bone calcium deposition of cartilage.
In a second aspect of the present invention, provide above-mentioned skeleton health-care product or the application of pharmaceutical composition in preparation skeleton health-care product or medicine.For example, by being mixed, this skeleton health-care product or pharmaceutical composition and edibility adjuvant or pharmaceutically acceptable carrier etc. make skeleton health-care product or medicine.
For example, a kind of skeleton health-care product or medicine can prepare by the following method: 1, all raw materials are crossed 60 mesh sieves; 2, take by weighing each raw material by formula proportion; 3, mix: the mixer rotating speed is 60 rev/mins, and incorporation time is 45 minutes; 4, on the automatic capsule filling machine, 0# capsule, 0.58 gram/grain carry out capsule-filling; 5, capsule polishing; 6, bottling.
Beneficial effect of the present invention is specific as follows: skeleton health-care product of the present invention or pharmaceutical composition are comprised of the raw material of following portions by weight: the calcium carbonate of 160000～185000 weight portions, the vitamin D of 1～2 weight portion
3The phosphopeptide caseinate of 11000～13000 weight portions, the chondroitin sulfate of 30000～50000 weight portions, the ossein of the glucosamine hydrochloride of 80000～100000 weight portions and 50000～70000 weight portions, the manganese chloride of 1150～1500 weight portions, design ingenious uniqueness, mutually take between component together, bioavailability is high, can alleviate bone pain for increasing bone density and recover bone function raising immunity, obviously solve osteoporosis, bone pain, reach the symptoms such as osteoarthrosis afunction, and can be made into compound preparation, have no side effect, be suitable for large-scale promotion application.
The specific embodiment
In order more clearly to understand technology contents of the present invention, describe the present invention below by specific embodiment.
Embodiment 1 prescription screening
The purpose of this prescription screening is to study simple calcium and vitamin D supplement and increases on this basis the difference of compositions aspect the effect of increase bone density such as being conducive to bone matrix formation and antioxidation.
1.1, prescription forms and dosage
| Control formula | The research prescription | |
| Prescription forms | Calcium carbonate 99.9g, vitamin D3 5mg | Prescription 1, prescription 2, prescription 3 |
| People's dosage | 0.017g/kgBW | 0.058g/kg BW |
| The dosage of rat | 0.17g/kg BW | 0.58g/kg BW |
The first prescription (prescription 1): calcium carbonate 260g, vitamin D3 1.5mg, phosphopeptide caseinate 18g, chondroitin sulfate 70g, glucosamine hydrochloride 140g, ossein 90g, manganese chloride 2g;
The second prescription (prescription 2): calcium carbonate 185g, vitamin D3 1mg, phosphopeptide caseinate 13g, chondroitin sulfate 50g, glucosamine hydrochloride 80g, ossein 50g, manganese chloride 1.5g;
The third prescription (prescription 3): calcium carbonate 160g, vitamin D3 2mg, phosphopeptide caseinate 11g, chondroitin sulfate 30g, glucosamine hydrochloride 100g, ossein 70g, manganese chloride 115g;
1.2, laboratory animal: SPF level SD kind male and healthy rat provides the (quality certification number: No. the 003rd, middle section moving pipe word) by Chinese Academy of Sciences's Shanghai Experimental Animal Center, body weight: 71.26 ± 4.83g, pellet are also provided by Chinese Academy of Sciences's Shanghai Experimental Animal Center.
1.3 experiment grouping: control formula group and research prescription group are established in experiment, and other establishes a low calcium matched group (150mg/100g feedstuff).30 rats were quarantined under laboratory condition after the week, be divided at random three dosage groups, be respectively the control formula group, 1 group of research prescription, 2 groups of research prescriptions, 3 groups of research prescriptions, low calcium matched group, 10 every group, tested material (corresponding prescription) is mixed in the feedstuff and fed, by 10% conversion of body weight.Continuous 30 days.
1.4 observation index comprises that body weight and height mensuration are (behind the fasting 12h, measure body weight, height, 1 time weekly), the femur gravimetry (is put to death behind the animal feeding 30d, separate the right side femur, roasting to constant weight in 105 ℃ of baking boxs, weighing is key heavy), femoral bmd is measured and (is measured the femur mid point with dual intensity x light borne densitometers, the bone density of the fluff of distal end and sclerotin), calcium content of bone and feedstuff calcium content are measured (using aas determination), the rat growth promoter (is born ablactation rat all around after 1 week of laundering period, sub-cage rearing 30d.Drink deionized water to avoid from drinking-water, obtaining calcium.Measure weekly height, body weight once.Treatments of the sample: digest with bone calcium.Mensuration is carried out according to the step of atomic absorption spectrophotometer instrument description.Measure liquid, standard solution and blank and all use the lanthana solution dilution).
1.5 the statistical disposition data are carried out variance analysis with SPSS 10.0 software kits.
1.6 result
1.6.1 the variation of body weight and food utilization from table 1～2 as seen, each organizes body weight and food utilization index there was no significant difference between rat, shows that research prescription (prescription 1, prescription 2, prescription 3) has no significant effect the weight of animals and food utilization.
Table 1 prescription is on the impact (n=10) of rat body weight
Table 2 prescription is on the impact (n=10) of rat food utilization
1.6.2 the mensuration of height as seen from Table 3,2nd, respectively filled a prescription in 3,4 weeks treated animal height and low calcium matched group relatively increases, and learns by statistics check, and difference has significant (P＜0.05), long, each the prescription group of the 1st all heights of beginning with hang down the calcium matched group relatively, no significant difference; Research prescription treated animal the 2nd, 3,4 all heights and control formula group relatively increase, and learn by statistics check, and difference has significant (P＜0.05).
Table 3 prescription is on the impact (n=10) of rat height
Annotate: # represents and hangs down the calcium matched group relatively, P＜0.05; ★ represents to compare P＜0.05 with the control formula group.
1.6.3 the mensuration of femur weight, calcium content of bone as seen from Table 4, each fill a prescription treated animal right lateral thigh bone weight and low calcium matched group relatively increase, and learn by statistics check, and difference has significant (P＜0.05); Each fill a prescription treated animal right lateral thigh calcium content of bone and low calcium matched group relatively increase, and learn by statistics check, and difference has significant (P＜0.05); Research prescription group (prescription 1, prescription 2, prescription 3) animal femur weight and femur calcium content all are higher than the control formula group, learn by statistics check, and difference has significant (P＜0.05).
Table 4 prescription is on the impact of femur weight, calcium content of bone
| Group | Dosage (g/kgbw) | Femur weight (g) | Calcium content of bone (g/kg) |
| Low calcium matched group | 0.00 | 0.35±0.02 | 103.5±6.8 |
| Control formula | 0.17 | 0.40±0.04# | 146.7±11.3# |
| Research prescription 1 | 0.58 | 0.49±0.04#★ | 169.8±15.5#★ |
| Research prescription 2 | 0.58 | 0.49±0.06#★ | 169.7±17.5#★ |
| Research prescription 3 | 0.58 | 0.49±0.05#★ | 169.8±13.5#★ |
| The F value | 0.737 | 2.792 | |
| The P value | ＞0.05 | ＞0.05 |
Annotate: # represents and hangs down the calcium matched group relatively, P＜0.05; ★ represents to compare P＜0.05 with the control formula group.
1.6.4 the mensuration of bone density as seen from Table 5, bone density and the low calcium matched group of the fluff of prescription treated animal left side femur mid point, distal end and sclerotin relatively increase, difference all has significant (P＜0.05), research prescription group and control formula group relatively increase, and difference has significant (P＜0.05).
Table 5 prescription is on the impact of bone density
Annotate: # represents and hangs down the calcium matched group relatively, P＜0.05; ★ represents to compare P＜0.05 with the control formula group.
1.7 conclusion: control formula and research prescription (prescription 1, prescription 2, prescription 3) all have positive acting to body length, femur weight, calcium content of bone and the bone density of rat, but the effect of research prescription (prescription 1, prescription 2, prescription 3) is better than control formula, and difference all has significant (P＜0.05).
Embodiment 2 dose screenings
According to the result of prescription screening, selected research is filled a prescription as formula for a product, but need to do further screening to the dosage of prescription.Prescription 1 in the embodiment 1 is as example.
2.1 the experiment grouping experiment is established high, medium and low three dosage groups, dosage is respectively 0.29,0.58,1.74g/kg BW, is equivalent to 5,10,30 times of human body recommended amounts, and other establishes a low calcium matched group.Every group of 10 rats are mixed tested material in the feedstuff and to feed 30 days observation periods.
2.2 observation index and detection method are with prescription screening part.
2.3 result
Epidemiological Analysis by statistics, each dosage group is compared with low calcium matched group, and each observation index all is better than low calcium matched group, and significant difference is arranged.Middle dosage group is compared with low dose group, and significant difference is arranged.High dose group and middle dosage group have significant difference than there was no significant difference with the low dose group ratio.
2.4 conclusion: because high dose group is compared with middle dosage group, the no significant difference of each index, and consider cost of material and the convenience of taking, therefore finally adopted middle dosage assembly side.
The check of embodiment 3 functional experiments
1, under this laboratory condition, show for the result of rat oral gavage after 3 months with this preparation (prescription 1 among the embodiment 1) of 0.29g/kgbw, 0.58g/kgbw, 1.74g/kgbw dosage: height and the height value added in high dose group rat experiment latter stage are significantly higher than low calcium matched group; The bone density of high dose group rat femur center and distal end, femur weight, femur calcium content and TC are significantly greater than low calcium matched group; Basic, normal, high dosage group rat is taken in calcium and excrement calcium and middle and high dosage group rat urine calcium content and is significantly higher than low calcium matched group; Middle and high dosage group calcium in rats apparent absorption rate and Retention significantly are lower than the calcium matched group.Difference has significance (P＜0.01 or P＜0.05).The above indices of high dose group rat does not have significance (p＞0.05) with corresponding calcium carbonate control group comparing difference.Point out the effect that this preparation has increases rat bone density.
2, result
2.1 this preparation (prescription 1) on the impact of rat body weight, the results are shown in Table 6.The starting weight difference of respectively organizing rat before the experiment does not have significance (P＞0.05); The body weight value added of each dosage group rat is compared difference after the experiment with low calcium matched group does not have significance (P＞0.05), and the end-body of high dose group rat weighs and has a net increase of the value added difference of comparing with calcium carbonate control group does not have significance (P＞0.05).
This preparation of table 6 is on the impact of rat body weight
2.2 this preparation (prescription 1) on the impact of rat height, the results are shown in Table 7.The initial height of respectively organizing rat before the experiment does not have significant difference (P＞0.05); Calcium carbonate control group, high dose group test last height and the height value added is significantly higher than low calcium matched group (P＜0.05 or P＜0.01); The experiment end height of high dose group rat and value added thereof are compared difference with calcium carbonate control group do not have significance (P＞0.05).
This preparation of table 7 is on the impact of rat height
2.3 this preparation (prescription 1) on the impact of rat femur length and bone density, the results are shown in Table 8.Each organizes the femur length no significant difference (P＞0.05) of rat; Calcium carbonate control group, high dose group rat femur distal end bone density, femur center bone density are significantly higher than low calcium matched group (P＜0.05 or P＜0.01); Sample high dose group femur center bone density and femur distal end bone density are compared difference with calcium carbonate control group do not have significance (P＞0.05).
This preparation of table 8 is on the impact of rat femur length and bone density
2.4 this preparation (prescription 1) on the impact of rat femur weight and calcium content, the results are shown in Table 9.The femur weight of high dose group rat is significantly greater than low calcium matched group (P＜0.01), and the femur weight of high dose group rat is compared with corresponding calcium carbonate control group does not have significant difference (P＞0.05); The femur calcium content of high dose group rat and TC are significantly greater than low calcium matched group (P＜0.01).The femur calcium content of high dose group rat and TC are compared difference with corresponding calcium carbonate control group do not have significance (P＞0.05).
This preparation of table 9 is on the impact of rat femur weight, calcium content of bone and TC
TC=femur weight (g) * calcium content (mg/g)
2.5 the impact that this preparation (prescription 1) is taken in calcium, excrement calcium and urinated calcium rat the results are shown in Table 10.Each dosage group, calcium carbonate control group rat are taken in calcium and are significantly higher than low calcium matched group (P＜0.01), and the urine calcium content of basic, normal, high dosage group, calcium carbonate control group rat kind calcium and middle and high dosage group, calcium carbonate control group rat is significantly higher than low calcium matched group (P＜0.05 or P＜0.01); The absorption calcium of high dose group rat, excrement calcium and urine calcium output are compared difference with corresponding calcium carbonate control group do not have significance (P＞0.05).
This preparation of table 10 is on the impact of rat femur weight, calcium content of bone and TC
2.6 this preparation (prescription 1) on the impact of rat apparent absorption rate and calcium Retention, the results are shown in Table 11.The apparent absorption rate of middle and high dosage group, calcium carbonate control group calcium in rats significantly is lower than calcium matched group (P＜0.01).The apparent absorption rate of high dose group calcium is compared difference with corresponding calcium carbonate control group do not have significance (P＞0.05); The Retention of middle and high dosage group calcium carbonate control group calcium in rats significantly is lower than calcium matched group (P＜0.01); The Retention of high dose group calcium is compared difference with corresponding calcium carbonate control group do not have significance (P＞0.05).
This preparation of table 11 is on the impact of calcium in rats metabolism
Apparent absorption rate (%)=(taking in calcium-excrement calcium) taken in calcium * 100; Calcium Retention (%)=(taking in calcium-excrement calcium-urine calcium)/absorption calcium * 100
2.7 adopt respectively prescription 2 and prescription 3 to carry out the above-mentioned functions checking, the result is similar to the result of the test that adopts prescription 1 to obtain.
3, brief summary
Under this laboratory condition, show for the result of rat oral gavage after 3 months with this preparation of 0.29g/kgbw, 0.58g/kgbw, 1.74g/kgbw dosage (prescription 1, prescription 2, prescription 3): height and the height value added in high dose group rat experiment latter stage are significantly higher than low calcium matched group; The bone density of high dose group rat femur center and distal end, femur weight, femur calcium content and TC are significantly greater than low calcium matched group; Basic, normal, high dosage group rat is taken in calcium and excrement calcium and middle and high dosage group rat urine calcium content and is significantly higher than low calcium matched group; Middle and high dosage group calcium in rats apparent absorption rate and Retention significantly are lower than the calcium matched group.Difference has significance (P＜0.01 or P＜0.05).The above indices of high dose group rat does not have significance (P＞0.05) with corresponding calcium carbonate control group comparing difference.Point out this preparation (prescription 1, prescription 2, prescription 3) to have the effect that increases rat bone density.
Therefore, skeleton health-care product of the present invention or pharmaceutical composition can increase bone density, alleviate bone pain, recover the bone function and improve immunity, and its advantage is: 1, effectively promote calcareous absorption; 2, repair the osteoarthrosis cell, promote bone cell growth; Obviously increase bone density, prevent and treat osteoporosis; 3, effectively promote the skeleton collagen metabolism, stabilization of bony collagen network structure, activation muscles and bones, anti-curing arthritis and aching; 4, recover osteoarthrosis proper motion function; 5, reduce the fracture occurrence risk; 6, improve immunity of organisms; But 7 two-ways regulation human endocrine levels are improved the quality of living.
To sum up, skeleton health-care product of the present invention or pharmaceutical composition design ingenious uniqueness, mutually take between component together, bioavailability is high, can alleviate bone pain for increasing bone density and recover the bone function and improve immunity, obviously solve osteoporosis, bone pain, and the symptom such as osteoarthrosis afunction, and can be made into compound preparation, have no side effect, be suitable for large-scale promotion application.
In this description, the present invention is described with reference to its specific embodiment.But, still can make various modifications and conversion obviously and not deviate from the spirit and scope of the present invention.Therefore, description is regarded in an illustrative, rather than a restrictive.
Claims (8)
1. a skeleton health-care compositions is characterized in that, is comprised of the raw material of following portions by weight: the calcium carbonate of 160000～185000 weight portions, the vitamin D of 1～2 weight portion
3, the phosphopeptide caseinate of 11000～13000 weight portions, the chondroitin sulfate of 30000～50000 weight portions, the glucosamine hydrochloride of 80000 ~ 100000 weight portions, the manganese chloride of the ossein of 50000～70000 weight portions and 1150 ~ 1500 weight portions.
2. skeleton health-care compositions according to claim 1 is characterized in that, described calcium carbonate is 168000～180000 weight portions, described vitamin D
3It is 1～2 weight portion, described phosphopeptide caseinate is 11500～12500 weight portions, described chondroitin sulfate is 40000～50000 weight portions, described glucosamine hydrochloride is that 88000 ~ 95000 weight portions and described ossein are 55000～65000 weight portions, the manganese chloride of 1200 ~ 1450 weight portions.
3. skeleton health-care compositions according to claim 1 is characterized in that, described calcium carbonate is 173333 weight portions, described vitamin D
3Be 1 weight portion, described phosphopeptide caseinate is 12000 weight portions, and described chondroitin sulfate is 46667 weight portions, and described glucosamine hydrochloride is that 93333 weight portions and described ossein are 60000 weight portions, and described manganese chloride is 1333 weight portions.
4. the application of skeleton health-care compositions according to claim 1 in preparation skeleton health-care product.
5. a skeleton pharmaceutical composition is characterized in that, is comprised of the raw material of following portions by weight: the calcium carbonate of 160000～185000 weight portions, the vitamin D of 1～2 weight portion
3, the phosphopeptide caseinate of 11000～13000 weight portions, the chondroitin sulfate of 30000～50000 weight portions, the glucosamine hydrochloride of 80000 ~ 100000 weight portions, the manganese chloride of the ossein of 50000～70000 weight portions and 1150 ~ 1500 weight portions.
6. skeleton pharmaceutical composition according to claim 5 is characterized in that, described calcium carbonate is 168000～180000 weight portions, described vitamin D
3It is 1～2 weight portion, described phosphopeptide caseinate is 11500～12500 weight portions, described chondroitin sulfate is 40000～50000 weight portions, described glucosamine hydrochloride is that 88000 ~ 95000 weight portions and described ossein are 55000～65000 weight portions, the manganese chloride of 1200 ~ 1450 weight portions.
7. skeleton pharmaceutical composition according to claim 5 is characterized in that, described calcium carbonate is 173333 weight portions, described vitamin D
3Be 1 weight portion, described phosphopeptide caseinate is 12000 weight portions, and described chondroitin sulfate is 46667 weight portions, and described glucosamine hydrochloride is that 93333 weight portions and described ossein are 60000 weight portions, and described manganese chloride is 1333 weight portions.
8. the application of skeleton pharmaceutical composition according to claim 5 in the medicine of preparation treatment osteoporosis, bone pain or osteoarthrosis afunction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110066234 CN102133395B (en) | 2011-03-18 | 2011-03-18 | Skeleton health-care product or medicinal composite and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110066234 CN102133395B (en) | 2011-03-18 | 2011-03-18 | Skeleton health-care product or medicinal composite and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102133395A CN102133395A (en) | 2011-07-27 |
| CN102133395B true CN102133395B (en) | 2013-04-10 |
Family
ID=44293407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110066234 Active CN102133395B (en) | 2011-03-18 | 2011-03-18 | Skeleton health-care product or medicinal composite and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102133395B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103250945A (en) * | 2012-03-08 | 2013-08-21 | 山东德圣医药科技有限公司 | Health-care food for enhancing bone mineral density |
| CN103250946A (en) * | 2012-03-08 | 2013-08-21 | 山东德圣医药科技有限公司 | Health-care food for enhancing bone mineral density |
| CN103301149B (en) * | 2012-03-12 | 2015-04-08 | 深圳市麦金利实业有限公司 | Medicinal preparation capable of increasing bone mineral density and improving osteoporosis |
| CN103251671B (en) * | 2012-12-28 | 2015-11-18 | 北京中研同仁堂医药研发有限公司 | A kind of composition and method of making the same containing Chinese medicine increasing bone density |
| CN103082297A (en) * | 2013-02-05 | 2013-05-08 | 山西振东五和健康食品股份有限公司 | Bone mineral density increase and joint healthcare food and its preparation method |
| CN103520711A (en) * | 2013-10-24 | 2014-01-22 | 北京一品堂医药科技有限公司 | Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition |
| CN104353064B (en) * | 2014-10-05 | 2016-09-07 | 刘兴宇 | For increasing bone density, the composition alleviating Osteoarthritis and preparation method thereof |
| CN105194657A (en) * | 2015-09-18 | 2015-12-30 | 威海康宝生物科技开发有限公司 | Preparation for increasing bone density and preparation method thereof |
| CN105056216A (en) * | 2015-09-23 | 2015-11-18 | 北京里肯营养科学研究有限公司 | Calcium supplementing preparation/granule and preparation method thereof |
| CN105268032B (en) * | 2015-10-30 | 2018-05-04 | 大连大学 | Promote the resorbable membrane of P15 bone-grafting material skeletonization |
| CN105410941A (en) * | 2015-12-08 | 2016-03-23 | 湖南洞庭水殖珍珠有限公司 | Serene Tablet health-care food capable of increasing bone density and strengthening immunity and preparation method thereof |
| CN107348522A (en) * | 2017-08-14 | 2017-11-17 | 北京市营养源研究所 | A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof |
| CN109380721A (en) * | 2018-09-29 | 2019-02-26 | 内蒙古蒙肽生物工程有限公司 | A kind of comprehensive composition and preparation method thereof for adjusting treating bone diseases |
| CN111729030A (en) * | 2020-08-11 | 2020-10-02 | 阮树月 | Compound bone collagen and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015682A (en) * | 2007-02-01 | 2007-08-15 | 甘肃奇正藏药有限公司 | Medicine composition with compact bone substance density improving function, preparing process and quality controlling means thereof |
| CN101248882A (en) * | 2008-03-28 | 2008-08-27 | 北京东方兴企食品工业技术有限公司 | Nutrition food product with promoting health of bones and bone arthrosis |
| CN101559218A (en) * | 2009-02-16 | 2009-10-21 | 北京因科瑞斯医药科技有限公司 | Composition with function of increasing bone density |
-
2011
- 2011-03-18 CN CN 201110066234 patent/CN102133395B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015682A (en) * | 2007-02-01 | 2007-08-15 | 甘肃奇正藏药有限公司 | Medicine composition with compact bone substance density improving function, preparing process and quality controlling means thereof |
| CN101248882A (en) * | 2008-03-28 | 2008-08-27 | 北京东方兴企食品工业技术有限公司 | Nutrition food product with promoting health of bones and bone arthrosis |
| CN101559218A (en) * | 2009-02-16 | 2009-10-21 | 北京因科瑞斯医药科技有限公司 | Composition with function of increasing bone density |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102133395A (en) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102133395B (en) | Skeleton health-care product or medicinal composite and application thereof | |
| Scholz-Ahrens et al. | Effect of oligofructose or dietary calcium on repeated calcium and phosphorus balances, bone mineralization and trabecular structure in ovariectomized rats | |
| CN103083650B (en) | Composition with bone mineral density addition function, and preparation method as well as application of composition | |
| CN103083648B (en) | Troche for enhancing bone mineral density based on milk mineral salt as raw material as well as preparation method thereof | |
| CN104705658B (en) | Health food with bone density improving function | |
| CN105796662A (en) | Psyllium seed husk powder and inulin composition | |
| CN105363023A (en) | Composition with effects of protecting joints and increasing bone mineral density and preparation method of composition | |
| CN102805858B (en) | High-efficiency calcium supplement capsule and preparation method thereof | |
| CN105056216A (en) | Calcium supplementing preparation/granule and preparation method thereof | |
| EA019837B1 (en) | Use of 25-hydroxy-vitamin d3 to affect human muscle physiology | |
| CN102178933A (en) | Preparation for preventing and treating osteoporosis and osteoarthrosis | |
| Kitchin et al. | Not just calcium and vitamin D: other nutritional considerations in osteoporosis | |
| CN104206949A (en) | Composition for improving osteoporosis and increasing bone mineral density, preparation method of same and application of the same in preparation of health-caring product | |
| CN107047937A (en) | A kind of dog newborn nutritious calcium tablet of sheep and preparation method thereof | |
| CN104146260B (en) | A kind of health food increasing bone density and preparation method thereof | |
| CN102551045A (en) | Collagen calcium tablet | |
| CN101279089B (en) | Donkey-hide gelatin calcium composition and preparing process thereof | |
| CN101732396B (en) | Method for preparing cucumber seed fermented material | |
| CN103349674A (en) | Tortoise shell rana japonica oil composition for increasing bone density and preventing osteoporosis | |
| CN102626463A (en) | Natural medicine compound for increasing bone mineral density and preventing and treating osteoporosis | |
| CN104523804B (en) | A kind of capsule for increasing bone density and preparation method thereof | |
| CN101690589B (en) | Heath product for increasing bone density and preparation method thereof | |
| CN1301160A (en) | Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty | |
| CN102000110A (en) | Composition used for preventing or treating bone and joint diseases and preparation method thereof | |
| CN102626420B (en) | Mixed preparation containing strontium, calcium and vitamin D |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230817 Address after: Plot c16-3, phase V, Shuofang industrial concentration zone, Xinwu District, Wuxi City, Jiangsu Province, 214000 Patentee after: Wuxi haiweisen Biotechnology Co.,Ltd. Address before: Room 308, Building 8, No. 579 Guoquan Road, Yangpu District, Shanghai, 200433 Patentee before: SHANGHAI HAIWEI BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right |